| Abstrakt: |
Keywords: Aldolase; Antibodies; Apolipoproteins; Apoproteins; Bioengineering; Biotechnology; Blood Proteins; Drugs and Therapies; Enzymes and Coenzymes; Gastroenterology; Gene Therapy; Genetics; Health and Medicine; Hepatocytes; Immunoglobulins; Immunology; Lipoproteins; Patent Application; Proteins; Risk and Prevention EN Aldolase Antibodies Apolipoproteins Apoproteins Bioengineering Biotechnology Blood Proteins Drugs and Therapies Enzymes and Coenzymes Gastroenterology Gene Therapy Genetics Health and Medicine Hepatocytes Immunoglobulins Immunology Lipoproteins Patent Application Proteins Risk and Prevention 624 624 1 10/16/23 20231017 NES 231017 2023 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A patent application by the inventors Mueller, Christian (Concord, MA, US); Scheibler, Lukas (Telluride, CO, US), filed on September 12, 2022, was made available online on September 28, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. "In some embodiments, the expression vector further comprises a nucleotide sequence encoding a C3 inhibitor (e.g., an aptamer, an anti-C3 antibody, an anti-C3b antibody, a mammalian complement regulatory protein, or mini factor H). The expression vector of claim 6, further comprising a nucleotide sequence encoding a C3 inhibitor (e.g., an aptamer, an anti-C3 antibody, an anti-C3b antibody, a mammalian complement regulatory protein, or mini factor H). "In some embodiments, the expression vector further comprises a nucleotide sequence encoding a C3 inhibitor (e.g., an aptamer, an anti-C3 antibody, an anti-C3b antibody, a mammalian complement regulatory protein, or mini factor H). [Extracted from the article] |
